A new targeted therapy has shown promise for a difficult-to-treat subset of lung cancer. In a multinational phase 2 trial, the oral drug sunvozertinib produced durable tumor responses in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback